Bayer (FRA:BAYN) Share Price Crosses Above Two Hundred Day Moving Average of $61.01

Bayer AG (FRA:BAYN)’s stock price crossed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $61.01 and traded as high as $66.52. Bayer shares last traded at $65.96, with a volume of 1,735,764 shares changing hands.

Several brokerages have recently commented on BAYN. Nord/LB set a €64.00 ($74.42) price objective on shares of Bayer and gave the stock a “neutral” rating in a research report on Wednesday, August 21st. DZ Bank reaffirmed a “neutral” rating on shares of Bayer in a research report on Wednesday, August 21st. Deutsche Bank set a €70.00 ($81.40) price objective on shares of Bayer and gave the stock a “neutral” rating in a research report on Friday, August 9th. Sanford C. Bernstein set a €90.00 ($104.65) price objective on shares of Bayer and gave the stock a “buy” rating in a research report on Friday, August 9th. Finally, Berenberg Bank set a €67.00 ($77.91) price objective on shares of Bayer and gave the stock a “neutral” rating in a research report on Wednesday, July 31st. One investment analyst has rated the stock with a sell rating, ten have assigned a hold rating and eleven have assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average price target of €79.90 ($92.91).

The firm’s 50-day moving average is €64.49 and its 200-day moving average is €61.01.



About Bayer (FRA:BAYN)

Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.

Recommended Story: What is the Current Ratio?

Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.